Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI4736 in Advanced Colorectal Cancer
NCT02227667Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2014
- Primary completion
- Jun 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in colorectal cancer (CRC), sponsored by Memorial Sloan Kettering Cancer Center. Started Dec 2014; status: completed.
02
Drugs
durvalumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02227667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02227667.